Alex Rabinovitch, MD
Emeritus Senior Scientist, The Sanford Project, Sanford Research
Dr. Alexander Rabinovitch retired as the Todd and Linda Broin Chair and Director of The Sanford Project in 2014, having served on The Sanford Project team since its inception in 2009. He joined The Sanford Project team from the University of Alberta in Edmonton, Alberta, Canada. In years prior, Dr. Rabinovitch completed both his bachelor’s and medical degree at McGill University in Montreal, Canada, with post-graduate studies completed in Canada, Switzerland and the United States. Dr. Rabinovitch taught as a professor for more than 30 years at four influential universities located in three separate countries. He has served on 10 committees, including the Medical Science Review Committee for the Juvenile Diabetes Research Foundation (JDRF) in 2008, as well as several diabetes-focused editorial boards.
Known for his expertise in beta cell regeneration in diabetic patients, Dr. Rabinovitch has been invited to present his discoveries and findings at venues across the world. He has received numerous awards, including the Excellence in Clinical Research Award by the Juvenile Diabetes Research Foundation International in 2007. Aside from being a professor and a researcher, Dr. Rabinovitch is an inventor with two U.S. patented inventions under his belt and his most recent invention with a patent pending.
Known for his expertise in beta cell regeneration in diabetic patients, Dr. Rabinovitch is an emeritus senior scientist for The Sanford Project.
Rabinovitch A and Suarez-Pinzon WL: Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochemistry and Biophysics 48:159-163, 2007.
Suarez-Pinzon WL, Lakey JRT, Rabinovitch A: Combination therapy with glucagon-like peptide-1 and gastrin induces β-cell neogenesis from human pancreatic duct cells in islets transplanted in immunodeficient diabetic mice. Cell Transplantation 17:631-640, 2008.
Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall CH, Atkinson MA, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288, 2008.
Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycemia in nonobese diabetic mice. Diabetologia 52:1680-1682, 2009.